Joshua Higa
Vice President of Investor Relations
Replay available
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q1 2026 earnings conference call, held 2026-05-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Emil Kakas
Chief Executive Officer and President
Eric Harris
Chief Commercial Officer
Howard Horn
Chief Financial Officer
Eric Kronbez
Chief Medical Officer
Tazeen Ahmad
Analyst at Bank of America
Joseph Schwartz
Analyst at Larenc Partners
Maury Raycroft
Analyst at Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ultragenyx Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.120 Good afternoon and welcome to Ultragenyx first quarter 2026 financial results 00:00:05.120 -- 00:00:10.149 conference call. At this time, all participants are on a listen-only mode. 00:00:10.149 -- 00:00:14.155 At the end of the prepared remarks, you will have an opportunity to ask questions during 00:00:14.155 -- 00:00:19.465 the Q&A portion of the call. It is now my pleasure to introduce your host, 00:00:19.465 -- 00:00:24.089 Joshua Higa, Vice President of Investor Relations. 00:00:24.393 -- 00:00:28.395 Thank you. We have issued a press release detailing our financial results, which you 00:00:28.395 -- 00:00:31.800 can find on our website at Ultragenyx.com. 00:00:31.800 -- 00:00:36.967 Joining me on this call are Emil Kakas, Chief Executive Officer and President, Eric Harris, 00:00:36.967 -- 00:00:42.154 Chief Commercial Officer, Howard Horn, Chief Financial Officer, and Eric Kronbez, 00:00:42.154 -- 00:00:46.260 Chief Medical Officer. I'd like to remind everyone that during today's call, we will 00:00:46.260 -- 00:00:50.706 be making forward-looking statements. These statements are subject to certain risks and 00:00:50.706 -- 00:00:54.284 uncertainties, and our actual results may differ materially. 00:00:54.284 -- 00:00:58.087 Please refer to the risk factors discussed in our latest SEC filings. 00:00:58.087 -- 00:01:01.289 I'll now turn the call over to Emil. 00:01:01.871 -- 00:01:03.973 Thanks, Josh, and good afternoon, everyone. 00:01:03.973 -- 00:01:09.078 We are now in our 16th year since our founding, and this year is expected to be 00:01:09.078 -- 00:01:13.382 transformative with growing revenue and multiple new drug approvals. 00:01:13.382 -- 00:01:18.386 We're on track to well exceed $700 million in revenue from our g...